E-LIB Suche - Ergebnisse für: Abrisqueta, Pau

1

Polatuzumab vedotin plus rituximab and lenalidomide in pati..:

Abrisqueta, Pau ; González-Barca, Eva ; Panizo, Carlos...
The Lancet Haematology. 11 (2024) 2 - p. e136-e146 , 2024

Link: https://doi.org/10.1016/..

2

New Insights into First-Line Therapy in Diffuse Large B-Cel..:

Abrisqueta, Pau
Journal of Clinical Medicine. 13 (2024) 7 - p. 1929 , 2024

Link: https://doi.org/10.3390/..

3

Safety and efficacy of parsaclisib in combination with ritu..:

Sancho, Juan-Manuel ; Abrisqueta, Pau ; Kumar, Abhijeet...
Leukemia & Lymphoma. , 2024

Link: https://doi.org/10.1080/..

4

Ibrutinib followed by ofatumumab consolidation in previousl..:

Abrisqueta, Pau ; González-Barca, Eva ; Ferrà, Christelle...
eClinicalMedicine. 73 (2024) - p. 102642 , 2024

Link: https://doi.org/10.1016/..

5

New therapies for relapsed or refractory aggressive B‐cell ..:

Bastos‐Oreiro, Mariana ; Abrisqueta, Pau ; Gutierrez, Antonio...
HemaSphere. 8 (2024) 4 - p. , 2024

Link: https://doi.org/10.1002/..

6

IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients..:

Merryman, Reid W. ; Belada, David ; Sureda, Anna...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S454 , 2023

Link: https://doi.org/10.1016/..

7

PET‐based radiomics signature can predict durable responses..:

Ligero, Marta ; Simó, Marc ; Carpio, Cecilia...
eJHaem. 4 (2023) 4 - p. 1081-1088 , 2023

Link: https://doi.org/10.1002/..

8

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVID..:

Sureda, Anna ; Falchi, Lorenzo ; Leppa, Sirpa...
HemaSphere. 7 (2023) S3 - p. e5547136 , 2023

Link: https://doi.org/10.1097/..

9

Low‐risk HPLLs/ABC score patients with splenic marginal zon..:

Muntañola, Ana ; Villalobos, María Teresa ; González‐Villambrosia, Sonia...
British Journal of Haematology. 202 (2023) 4 - p. 776-784 , 2023

Link: https://doi.org/10.1111/..

10

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALI..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
HemaSphere. 7 (2023) S3 - p. e7389505 , 2023

Link: https://doi.org/10.1097/..

11

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T..:

Bastos-Oreiro, Mariana ; Gutierrez, Antonio ; Iacoboni, Gloria...
Transplantation and Cellular Therapy. 29 (2023) 12 - p. 747.e1-747.e10 , 2023

Link: https://doi.org/10.1016/..

12

A low total metabolic tumor volume independently predicts f..:

Mozas, Pablo ; Casanueva‐Eliceiry, Sebastian ; Rivero, Andrea...
Hematological Oncology. 42 (2023) 1 - p. , 2023

Link: https://doi.org/10.1002/..

13

POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S206 , 2023

Link: https://doi.org/10.1016/..

14

ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenal..:

Duell, Johannes ; Abrisqueta, Pau ; Dreyling, Martin...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S436-S437 , 2023

Link: https://doi.org/10.1016/..

15

Kinetics of cellular and humoral immunogenicity and effecti..:

Jiménez, Moraima ; Fernández‐Naval, Candela ; Navarro, Víctor...
American Journal of Hematology. 98 (2023) 8 - p. 1204-1213 , 2023

Link: https://doi.org/10.1002/..